Linked Data API

Show Search Form

Search Results

872272
registered interest false more like this
date less than 2018-03-26more like thismore than 2018-03-26
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Acute Lymphoblastic Leukaemia: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia. more like this
tabling member constituency Crawley more like this
tabling member printed
Henry Smith remove filter
uin 134186 remove filter
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-04-03more like thismore than 2018-04-03
answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN 134187 more like this
question first answered
less than 2018-04-03T13:25:08.103Zmore like thismore than 2018-04-03T13:25:08.103Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
3960
label Biography information for Henry Smith more like this